Market research
4OD.F Odonate Therapeutics, Inc
F EUR Not available
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 48M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- 0.0%
- Beta
- 0.18
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 48M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- 0.0%
- Beta
- 0.18
About
About Odonate Therapeutics, Inc
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4OD.F discussion.
5 years, 5 months ago
Odonate Therapeutics, Inc is currently in a long term downtrend where the price is trading 70.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Odonate Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 15.9% to $-32M since the same quarter in the previous year.
Finally, its free cash flow fell by 28.5% to $-32M since the same quarter in the previous year.
Based on the above factors, Odonate Therapeutics, Inc gets an overall score of 1/5.